PharmacyCodes



Megestrolo [DCIT] en es it fr

Megestrolo [DCIT] Brand names, Megestrolo [DCIT] Analogs

Megestrolo [DCIT] Brand Names Mixture

  • No information avaliable

Megestrolo [DCIT] Chemical_Formula

C7H7NO3

Megestrolo [DCIT] RX_link

http://www.rxlist.com/cgi/generic2/canasa.htm

Megestrolo [DCIT] fda sheet

Megestrolo_[DCIT] FDA

Megestrolo [DCIT] msds (material safety sheet)

Megestrolo_[DCIT] MSDS

Megestrolo [DCIT] Synthesis Reference

No information avaliable

Megestrolo [DCIT] Molecular Weight

153.135 g/mol

Megestrolo [DCIT] Melting Point

283 oC

Megestrolo [DCIT] H2O Solubility

0.84 g/L at 20°C

Megestrolo [DCIT] State

Solid

Megestrolo [DCIT] LogP

1.012

Megestrolo [DCIT] Dosage Forms

Rectal suppository (500 mg or 1000 mg)

Megestrolo [DCIT] Indication

For the treatment of active ulcerative proctitis.

Megestrolo [DCIT] Pharmacology

Sulfasalazine has been used in the treatment of ulcerative colitis for over 55 years. It is split by bacterial action in the colon into sulfapyridine (SP) and mesalamine (5-ASA). It is thought that the mesalamine component only is therapeutically active in ulcerative colitis.

Megestrolo [DCIT] Absorption

20 to 30% absorbed following oral administration. 10 to 35% absorbed from the colon (rectal suppository) - extent of absorption is determined by the length of time the drug is retained in the colon.

Megestrolo [DCIT] side effects and Toxicity

Oral, mouse: LD50 = 3370 mg/kg; Oral, rat: LD50 = 2800 mg/kg; Skin, rabbit: LD50 = >5 gm/kg. There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalamine absorption from the colon is limited.

Megestrolo [DCIT] Patient Information

Megestrolo [DCIT] Organisms Affected

Humans and other mammals